Pulmonx Corp. (LUNG) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Pulmonx Corporation is a commercial-stage medical technology company providing minimally invasive treatments for severe emphyma, primarily through its Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, and LungTraX Platform. This report covers the quarterly period ended September 30, 2025. The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $21.5 million | $20.4 million | $67.9 million | $60.0 million |
| Gross Margin | 74.7% | 73.7% | 73.0% | 74.0% |
| Net Loss | $(14.0) million | $(14.1) million | $(43.6) million | $(43.2) million |
| Loss Per Share (Basic/Diluted) | $(0.34) | $(0.36) | $(1.08) | $(1.11) |
| Cash & Equivalents | $76.5 million | $70.9 million | As of Sept 30, 2025 | |
| Total Debt (Net) | $37.1 million | $37.2 million | ||
| Operating Cash Flow (9M) | $(25.3) million | $(24.8) million | Used in operations |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5.5% year-over-year in Q3 and 13.1% for the nine-month period, driven by continued growth in Zephyr Valve procedure volumes in both the U.S. and international markets.
- Expense Trends: Research and Development (R&D) expenses rose 29.4% in Q3 and 9.9% for the nine months, primarily due to increased clinical trial costs (including the AeriSeal System) and personnel expenses. Selling, General, and Administrative (SG&A) expenses remained relatively flat in Q3 (+0.7%) but increased 4.4% for the nine months due to higher marketing spend.
- Debt Structure: In April 2025, the Company amended its CIBC Loan to extend the interest-only period through maturity (October 2027), deferring principal repayment. The effective interest rate was 8.8% as of September 30, 2025.
- Leadership Transition: In October 2025, following the filing date, the Company announced the resignation of CEO Steven Williamson and CFO Mehul Joshi. Glendon E. French returned as President and CEO, and Derrick Sung joined as COO and CFO.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash and cash equivalents ($76.5 million) are sufficient to fund operations for at least the next 12 months. The Company expects to continue incurring net losses for the foreseeable future.
- Outlook: The Company plans to continue investing in sales and marketing expansion, R&D for next-generation products, and clinical trials (specifically the CONVERT II trial for the AeriSeal System).
- Legal Contingency: The Company is in settlement discussions regarding a Qui Tam Action (False Claims Act) initiated in 2022. An estimated liability has been recorded, subject to approval by the USDOJ. The Company cannot estimate additional liability if approval is not obtained.
- Risks: Key risks include dependence on a single product (Zephyr Valve), reimbursement challenges, competition, reliance on single-source suppliers, and potential impacts of trade tariffs on manufacturing costs.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the CIBC Loan covenants, specifically the requirement to maintain unrestricted cash equal to the greater of $20 million or the absolute value of Adjusted EBITDA loss.
- Legal Settlement: Monitor the status of the Qui Tam Action settlement discussions and any potential additional liabilities if the USDOJ does not approve the current estimate.
- Leadership Transition: Assess the impact of the recent executive leadership changes on strategic execution and operational stability.
- Reimbursement Landscape: Track updates on Medicare and commercial payor coverage policies, as reimbursement remains a critical driver for adoption.
- Cash Burn Rate: Monitor the trajectory of operating cash burn ($25.3 million for 9M 2025) against the current cash balance to validate the 12-month liquidity runway.